Background It was urgent and necessary to synthesize the evidence for vaccine
effectiveness (VE) against SARS-CoV-2 variants of concern (VOC). We conducted a …

Since the outbreak of coronavirus disease 2019 (Covid‐19) in December 2019, caused by
the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the number of …

Abstract Coronavirus disease 2019 (COVID‐19) has brought about a great threat to global
public health. Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS …

Since the start of the COVID-19 pandemic, numerous variants of SARS-CoV-2 have been
reported worldwide. The advent of variants of concern (VOCs) raises severe concerns amid …

Background Emerging and future SARS-CoV-2 variants may jeopardize the effectiveness of
vaccination campaigns. Therefore, it is important to know how the different vaccines perform …

Billions of doses of coronavirus disease 2019 (COVID-19) vaccines have been administered
globally, dramatically reducing severe acute respiratory syndrome coronavirus 2 (SARS …

Background Aging influences COVID-19 severity and response to vaccination, but previous
vaccine effectiveness (VE) analyzes lack the power to evaluate its role in subgroups within …

The COVID‐19 pandemic is going into its third year with Europe again being the focus of
major epidemic activity. The present review tries to answer the question whether one can …

Multiple studies of vaccinated and convalescent cohorts have demonstrated that serum
neutralizing antibody (nAb) titers correlate with protection against coronavirus disease 2019 …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus that belongs to
the coronavirus family and is the cause of coronavirus disease 2019 (COVID-19). As of May …